Kalamazoo, Michigan - October 22, 2015 - Stryker Corporation (NYSE:SYK) reported operating results for the third quarter of 2015:
Third Quarter Highlights
Net sales grew 1.3% to $2.4 billion (5.9% constant currency)
| Orthopaedics | 0.3 | % | or | 5.8% constant currency |
| MedSurg | 0.6 | % | or | 4.1% constant currency |
| Neurotechnology and Spine | 5.0 | % | or | 9.9% constant currency |
Reported diluted net earnings per share increased 393.8% to $0.79
Adjusted diluted net earnings per share(1) increased 8.7% to $1.25
"We delivered another solid quarter with organic sales again exceeding 5%, putting us on pace to achieve our sales and adjusted EPS targets for 2015," said Kevin A. Lobo, Chairman and Chief Executive Officer. "I am pleased with our disciplined execution as we work with our customers to make healthcare better."
Sales Analysis
Consolidated net sales of $2.4 billion increased 1.3% in the quarter as reported and 5.9% in constant currency, as net sales were negatively impacted by 4.6% due to the impact of foreign currency exchange rates. Excluding the 0.6% impact of acquisitions, net sales in the quarter increased 5.3% in constant currency, including 6.6% from increased unit volume partially offset by 1.3% lower prices.
Orthopaedics net sales of $1.0 billion increased 0.3% in the quarter as reported and 5.8% in constant currency, as net sales were negatively impacted by 5.5% due to the impact of foreign currency exchange rates. Excluding the 0.3% impact of acquisitions, net sales in the quarter increased 5.5% in constant currency, including 7.7% from increased unit volume partially offset by 2.2% lower prices.
MedSurg net sales of $943 million increased 0.6% in the quarter as reported and 4.1% in constant currency, as net sales were negatively impacted by 3.5% due to the impact of foreign currency exchange rates. Excluding the 1.3% impact of acquisitions, net sales in the quarter increased 2.8% in constant currency, including 2.9% from increased unit volume partially offset by 0.1% lower prices.
Neurotechnology and Spine net sales of $458 million increased 5.0% in the quarter as reported and 9.9% in constant currency, as net sales were negatively impacted by 4.9% due to the impact of foreign currency exchange rates. Net sales in the quarter in constant currency increased 11.7% from increased unit volume partially offset by 1.7% lower prices.
Earnings Analysis
Reported net earnings of $301 million increased 428.1% in the quarter. Reported diluted net earnings per share of $0.79 increased 393.8% in the quarter. Reported net earnings include charges for the Rejuvenate and ABG II recall, tax matters, acquisition and integration related activities, additional cost of sales for inventory sold that was "stepped up" to fair value related to acquisitions, and restructuring-related activities. The effect of each of these matters on reported net earnings and diluted net earnings per share appears in the reconciliation of GAAP to non-GAAP financial measures provided below. Excluding the impact of these charges, reduces reported gross profit margin in the quarter from 67.1% to 66.9% and increases reported operating income margin in the quarter from 15.6% to 24.9%.
Excluding the impact of the items described above, adjusted net earnings(2) of $476 million increased 8.4% in the quarter. Adjusted diluted net earnings per share(1) of $1.25 increased 8.7% in the quarter.
2015 Outlook
We expect 2015 constant currency sales growth in the range of 6.5% to 7.5%, including organic sales growth in the range of 5.5% to 6.5%. Based on current foreign currency exchange rates, we expect adjusted diluted net earnings per share to be in the range of $5.07-$5.12 for the full year. If foreign currency exchange rates hold near current levels, we expect sales in the full year of 2015 to be negatively impacted by approximately 4.0% and adjusted diluted net earnings per share to be negatively impacted by approximately $0.25 in the full year.
(1) A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, and other important information, appears below.
(2) A reconciliation of reported net earnings to adjusted net earnings, a non-GAAP financial measure, and other important information, appears below.
Conference Call on Thursday, October 22, 2015
As previously announced, the Company will host a conference call on Thursday, October 22, 2015 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended September 30, 2015 and provide an operational update.
To participate in the conference call dial (866) 436-9172 (domestic) or (630) 691-2760 (international) and be prepared to provide confirmation number 3831 3505 to the operator.
A simultaneous webcast of the call will be accessible via the Company's website at www.stryker.com. The call will be archived on this site for 90 days.
A recording of the call will also be available from 8:30 p.m., Eastern Time, on Thursday, October 22, 2015, until 11:59 p.m., Eastern Time, on Thursday, October 29, 2015. To hear this recording you may dial (888) 843-7419 (domestic) or (630) 652-3042 (international) and enter the passcode 3831 3505 #.
Caution Concerning Forward-Looking Statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world.
Please contact us for more information at www.stryker.com.
For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com
STRYKER CORPORATION
For the Three and Nine Months Ended September 30, 2015 and 2014
(Unaudited - Millions of Dollars, Except Per Share Amounts)
CONDENSED STATEMENTS OF EARNINGS |
| | Three Months | | Nine Months |
| | 2015 | 2014 | % Change | | 2015 | 2014 | % Change |
| Net Sales | $ | 2,420 | | $ | 2,389 | | 1.3 | | | $ | 7,231 | | $ | 7,057 | | 2.5 | |
| Cost of Sales | 796 | | 829 | | (4.0 | ) | | 2,449 | | 2,420 | | 1.2 | |
| Gross Profit | 1,624 | | 1,560 | | 4.1 | | | 4,782 | | 4,637 | | 3.1 | |
| % of sales | 67.1 | % | 65.3 | % | | | 66.1 | % | 65.7 | % | |
| Research, development and engineering expenses | 155 | | 153 | | 1.3 | | | 461 | | 461 | | - | |
| Selling, general and administrative expenses | 887 | | 878 | | 1.0 | | | 2,640 | | 2,607 | | 1.3 | |
| Recall charges | 150 | | 29 | | 417.2 | | | 316 | | 649 | | (51.3 | ) |
| Intangible asset amortization | 54 | | 50 | | 8.0 | | | 152 | | 142 | | 7.0 | |
| Total Operating Expenses | 1,246 | | 1,110 | | 12.3 | | | 3,569 | | 3,859 | | (7.5 | ) |
| Operating Income | 378 | | 450 | | (16.0 | ) | | 1,213 | | 778 | | 55.9 | |
| % of sales | 15.6 | % | 18.8 | % | | | 16.8 | % | 11.0 | % | |
| Other income (expense), net | (33 | ) | (25 | ) | 32.0 | | | (90 | ) | (79 | ) | 13.9 | |
| Earnings before income taxes | 345 | | 425 | | (18.8 | ) | | 1,123 | | 699 | | 60.7 | |
| Income Taxes | 44 | | 368 | | (88.0 | ) | | 206 | | 444 | | (53.6 | ) |
| Net Earnings | $ | 301 | | $ | 57 | | 428.1 | | | $ | 917 | | $ | 255 | | 259.6 | |
| Net earnings per share of common stock: | | | | | | | |
| Basic | $ | 0.80 | | $ | 0.16 | | 400.0 | | | $ | 2.43 | | $ | 0.68 | | 257.4 | |
| Diluted | $ | 0.79 | | $ | 0.16 | | 393.8 | | | $ | 2.40 | | $ | 0.67 | | 258.2 | |
| Weighted-average shares outstanding - in millions: | | | | | | | |
| Basic | 376.3 | | 378.4 | | | | 377.4 | | 378.5 | | |
| Diluted | 380.7 | | 382.5 | | | | 381.8 | | 382.7 | | |
| CONDENSED BALANCE SHEETS |
| | September | December |
| | 2015 | 2014 |
| ASSETS | | |
| Cash and cash equivalents | $ | 3,163 | | $ | 1,795 | |
| Marketable securities | 209 | | 3,205 | |
| Accounts receivable, (net) | 1,496 | | 1,572 | |
| Inventories | 1,665 | | 1,588 | |
| Other current assets | 1,500 | | 1,513 | |
| Total Current Assets | 8,033 | | 9,673 | |
| Property, plant and equipment, (net) | 1,128 | | 1,098 | |
| Goodwill and other intangibles, (net) | 6,021 | | 6,204 | |
| Other assets | 735 | | 738 | |
| Total Assets | $ | 15,917 | | $ | 17,713 | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | |
| Current liabilities | 2,856 | | 2,871 | |
| Accrued recall expenses | 697 | | 1,593 | |
| Other liabilities | 1,369 | | 1,408 | |
| Long-term debt, excluding current maturities | 2,511 | | 3,246 | |
| Shareholders' equity | 8,484 | | 8,595 | |
| Total liabilities and shareholders' equity | $ | 15,917 | | $ | 17,713 | |
| CONDENSED STATEMENTS OF CASH FLOWS |
| | Nine Months |
| | 2015 | 2014 |
| Operating activities | | |
| Net earnings | $ | 917 | | $ | 255 | |
| Depreciation | 137 | | 140 | |
| Intangibles amortization | 152 | | 142 | |
| Changes in operating assets and liabilities and other, net | (978 | ) | 566 | |
| Net cash provided by operating activities | 228 | | 1,103 | |
| Investing activities | | |
| Acquisitions, net of cash acquired | (140 | ) | (825 | ) |
| Change in marketable securities, net | 2,872 | | (793 | ) |
| Purchases of property, plant and equipment | (191 | ) | (172 | ) |
| Net cash provided by (used in) investing activities | 2,541 | | (1,790 | ) |
| Financing activities | | |
| Borrowings of debt (repayments of debt), net | (501 | ) | 1,195 | |
| Dividends paid | (391 | ) | (346 | ) |
| Repurchase and retirement of common stock | (446 | ) | (100 | ) |
| Other financing | 36 | | (38 | ) |
| Net cash (used in) provided by financing activities | (1,302 | ) | 711 | |
| Effect of exchange rate changes on cash and cash equivalents | (99 | ) | (7 | ) |
| Change in cash and cash equivalents | $ | 1,368 | | $ | 17 | |
STRYKER CORPORATION
For the Three and Nine Months Ended September 30, 2015
(Unaudited - Millions of Dollars)
SUPPLEMENTAL SALES GROWTH ANALYSES |
| | Three Months | | Nine Months |
| | | | % Change | | | | % Change |
| | 2015 | 2014 | As Reported | Constant Currency | | 2015 | 2014 | As Reported | Constant Currency |
| Geographic sales: | | | | | | | | | |
| United States | $ | 1,756 | | $ | 1,628 | | 7.8 | % | 7.8 | % | | $ | 5,145 | | $ | 4,740 | | 8.5 | % | 8.5 | % |
| International | 664 | | 761 | | (12.6 | )% | 1.8 | % | | 2,086 | | 2,317 | | (10.0 | )% | 3.8 | % |
| Total Net Sales | $ | 2,420 | | $ | 2,389 | | 1.3 | % | 5.9 | % | | $ | 7,231 | | $ | 7,057 | | 2.5 | % | 7.0 | % |
| Worldwide sales: | | | | | | | | | |
| Orthopaedics | $ | 1,019 | | $ | 1,016 | | 0.3 | % | 5.8 | % | | $ | 3,077 | | $ | 3,043 | | 1.1 | % | 6.5 | % |
| MedSurg | 943 | | 936 | | 0.6 | % | 4.1 | % | | 2,809 | | 2,727 | | 3.0 | % | 6.4 | % |
| Neurotechnology and Spine | 458 | | 437 | | 5.0 | % | 9.9 | % | | 1,345 | | 1,287 | | 4.5 | % | 9.4 | % |
| Total Net Sales | $ | 2,420 | | $ | 2,389 | | 1.3 | % | 5.9 | % | | $ | 7,231 | | $ | 7,057 | | 2.5 | % | 7.0 | % |
| |
| | Three Months |
| | | | % Change |
| | | | | | U.S. | International |
| | 2015 | 2014 | As Reported | Constant Currency | As Reported | As Reported | Constant Currency |
| Orthopaedics | | | | | | | |
| Knees | $ | 332 | | $ | 335 | | (1.1 | )% | 3.5 | % | 5.0 | % | (14.9 | )% | 0.2 | % |
| Hips | 307 | | 316 | | (2.9 | )% | 3.1 | % | 5.7 | % | (14.6 | )% | (0.4 | )% |
| Trauma and Extremities | 318 | | 309 | | 2.9 | % | 9.1 | % | 15.1 | % | (12.5 | )% | 1.5 | % |
| Other | 62 | | 56 | | 12.6 | % | 16.7 | % | 20.7 | % | (14.3 | )% | 3.3 | % |
| ORTHOPAEDICS | $ | 1,019 | | $ | 1,016 | | 0.3 | % | 5.8 | % | 9.0 | % | (13.9 | )% | 0.5 | % |
| | | | | | | | |
| MedSurg | | | | | | | |
| Instruments | 359 | | 348 | | 2.8 | % | 6.6 | % | 8.1 | % | (12.8 | )% | 2.1 | % |
| Endoscopy | 336 | | 345 | | (2.5 | )% | 1.4 | % | 3.4 | % | (16.9 | )% | (3.5 | )% |
| Medical | 195 | | 190 | | 2.5 | % | 5.7 | % | 5.4 | % | (9.4 | )% | 6.9 | % |
| Sustainability | 53 | | 53 | | (0.4 | )% | (0.3 | )% | (0.4 | )% | (0.3 | )% | 19.8 | % |
| MEDSURG | $ | 943 | | $ | 936 | | 0.6 | % | 4.1 | % | 5.3 | % | (14.1 | )% | 0.4 | % |
| | | | | | | | |
| Neurotechnology and Spine | | | | | | | |
| Neurotechnology | 275 | | 251 | | 9.8 | % | 15.9 | % | 15.7 | % | (0.2 | )% | 16.3 | % |
| Spine | 183 | | 186 | | (1.5 | )% | 1.9 | % | 6.1 | % | (18.6 | )% | (7.5 | )% |
| NEUROTECHNOLOGY AND SPINE | $ | 458 | | $ | 437 | | 5.0 | % | 9.9 | % | 11.4 | % | (7.2 | )% | 7.2 | % |
| | | | | | | | |
| | | | | | | | |
| | Nine Months |
| | | | % Change |
| | | | | | U.S. | International |
| | 2015 | 2014 | As Reported | Constant Currency | As Reported | As Reported | Constant Currency |
| Orthopaedics | | | | | | | |
| Knees | $ | 1,023 | | $ | 1,033 | | (1.0 | )% | 3.4 | % | 3.4 | % | (10.7 | )% | 3.4 | % |
| Hips | 939 | | 960 | | (2.2 | )% | 3.5 | % | 6.3 | % | (13.4 | )% | (0.2 | )% |
| Trauma and Extremities | 940 | | 895 | | 5.1 | % | 11.6 | % | 17.0 | % | (9.4 | )% | 4.9 | % |
| Other | 175 | | 155 | | 13.1 | % | 16.8 | % | 22.2 | % | (13.8 | )% | 0.8 | % |
| ORTHOPAEDICS | $ | 3,077 | | $ | 3,043 | | 1.1 | % | 6.5 | % | 9.0 | % | (11.3 | )% | 2.6 | % |
| | | | | | | | |
| MedSurg | | | | | | | |
| Instruments | 1,059 | | 1,031 | | 2.6 | % | 6.5 | % | 7.0 | % | (9.5 | )% | 5.0 | % |
| Endoscopy | 992 | | 993 | | (0.1 | )% | 3.5 | % | 5.3 | % | (12.9 | )% | (0.7 | )% |
| Medical | 597 | | 548 | | 8.9 | % | 11.9 | % | 11.6 | % | (1.4 | )% | 13.3 | % |
| Sustainability | 161 | | 155 | | 4.2 | % | 4.2 | % | 4.2 | % | (3.7 | )% | 10.8 | % |
| MEDSURG | $ | 2,809 | | $ | 2,727 | | 3.0 | % | 6.4 | % | 7.2 | % | (9.6 | )% | 3.9 | % |
| | | | | | | | |
| Neurotechnology and Spine | | | | | | | |
| Neurotechnology | 799 | | 739 | | 8.1 | % | 14.0 | % | 15.2 | % | (3.0 | )% | 12.3 | % |
| Spine | 546 | | 548 | | (0.2 | )% | 3.0 | % | 5.7 | % | (14.0 | )% | (3.2 | )% |
| NEUROTECHNOLOGY AND SPINE | $ | 1,345 | | $ | 1,287 | | 4.5 | % | 9.4 | % | 10.8 | % | (7.0 | )% | 6.7 | % |
SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted operating income; adjusted effective income tax rate; adjusted net earnings; and adjusted diluted net earnings per share. We believe that these non-GAAP measures provide meaningful information to assist shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.
To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current year results at prior year average foreign currency exchange rates. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates and acquisitions that affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year results at prior year average foreign currency exchange rates excluding the impact of acquisitions. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, operating income, effective income tax rate, net earnings and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures:
STRYKER CORPORATION
For the Three and Nine Months Ended September 30, 2015 and 2014
(Unaudited - Millions of Dollars, Except Per Share Amounts)
RECONCILIATION OF ACTUAL RESULTS TO ADJUSTED RESULTS |
| 2015 Three Months | Gross Profit | Selling, General & Administrative Expenses | Intangible Amortization | Operating Income | Net Earnings | Effective Tax Rate | Diluted EPS |
| AS REPORTED | $ | 1,624 | | $ | 887 | | $ | 54 | | $ | 378 | | $ | 301 | | 12.8 | % | $ | 0.79 | |
| Acquisition and integration related charges (a) | | | | | | | |
| Inventory stepped up to fair value | (6 | ) | - | | - | | (6 | ) | (4 | ) | (0.3 | ) | (0.01 | ) |
| Other acquisition and integration related | - | | (5 | ) | - | | 5 | | 5 | | (0.2 | ) | 0.01 | |
| Amortization of intangible assets | - | | - | | (54 | ) | 54 | | 38 | | 2.1 | | 0.12 | |
| Restructuring related charges (b) | 2 | | (20 | ) | - | | 22 | | 15 | | 0.3 | | 0.04 | |
| Rejuvenate and other recall matters (c) | - | | - | | - | | 150 | | 127 | | 0.3 | | 0.32 | |
| Tax matters (e) | - | | - | | - | | - | | (6 | ) | 1.4 | | (0.02 | ) |
| ADJUSTED | $ | 1,620 | | $ | 862 | | $ | - | | $ | 603 | | $ | 476 | | 16.4 | % | $ | 1.25 | |
| 2014 Three Months | Gross Profit | Selling, General & Administrative Expenses | Intangible Amortization | Operating Income | Net Earnings | Effective Tax Rate | Diluted EPS |
| AS REPORTED | $ | 1,560 | | $ | 878 | | $ | 50 | | $ | 450 | | $ | 57 | | 86.6 | % | $ | 0.16 | |
| Acquisition and integration related charges (a) | | | | | | | |
| Inventory stepped up to fair value | 10 | | - | | - | | 10 | | 6 | | 0.5 | | 0.02 | |
| Other acquisition and integration related | - | | (14 | ) | - | | 14 | | 11 | | 0.1 | | 0.03 | |
| Amortization of intangible assets | - | | - | | (50 | ) | 50 | | 34 | | 1.4 | | 0.09 | |
| Restructuring related charges (b) | (1 | ) | (20 | ) | - | | 19 | | 8 | | 1.7 | | 0.02 | |
| Rejuvenate and other recall matters (c) | - | | - | | - | | 29 | | 23 | | 0.1 | | 0.06 | |
| Tax matters (e) | - | | - | | - | | - | | 300 | | (70.5 | ) | 0.77 | |
| ADJUSTED | $ | 1,569 | | $ | 844 | | $ | - | | $ | 572 | | $ | 439 | | 19.9 | % | $ | 1.15 | |
| 2015 Nine Months | Gross Profit | Selling, General & Administrative Expenses | Intangible Amortization | Operating Income | Net Earnings | Effective Tax Rate | Diluted EPS |
| AS REPORTED | $ | 4,782 | | $ | 2,640 | | $ | 152 | | $ | 1,213 | | $ | 917 | | 18.3 | % | $ | 2.40 | |
| Acquisition and integration related charges (a) | | | | | | | |
| Inventory stepped up to fair value | 7 | | - | | - | | 7 | | 4 | | 0.2 | | 0.01 | |
| Other acquisition and integration related | - | | (24 | ) | - | | 24 | | 18 | | 0.2 | | 0.05 | |
| Amortization of intangible assets | - | | - | | (152 | ) | 152 | | 107 | | 1.6 | | 0.30 | |
| Restructuring related charges (b) | 4 | | (74 | ) | - | | 78 | | 58 | | 0.3 | | 0.15 | |
| Rejuvenate and other recall matters (c) | - | | - | | - | | 316 | | 222 | | 3.8 | | 0.57 | |
| Legal matters (d) | - | | 53 | | - | | (53 | ) | (46 | ) | 0.2 | | (0.12 | ) |
| Tax matters (e) | - | | - | | - | | - | | 78 | | (7.0 | ) | 0.20 | |
| ADJUSTED | $ | 4,793 | | $ | 2,595 | | $ | - | | $ | 1,737 | | $ | 1,358 | | 17.6 | % | $ | 3.56 | |
| 2014 Nine Months | Gross Profit | Selling, General & Administrative Expenses | Intangible Amortization | Operating Income | Net Earnings | Effective Tax Rate | Diluted EPS |
| AS REPORTED | $ | 4,637 | | $ | 2,607 | | $ | 142 | | $ | 778 | | $ | 255 | | 63.5 | % | $ | 0.67 | |
| Acquisition and integration related charges (a) | | | | | | | |
| Inventory stepped up to fair value | 24 | | - | | - | | 24 | | 15 | | 0.5 | | 0.04 | |
| Other acquisition and integration related | - | | (46 | ) | - | | 46 | | 32 | | 0.6 | | 0.08 | |
| Amortization of intangible assets | - | | - | | (142 | ) | 142 | | 99 | | 1.6 | | 0.26 | |
| Restructuring related charges (b) | - | | (54 | ) | - | | 54 | | 37 | | 0.7 | | 0.10 | |
| Rejuvenate and other recall matters (c) | - | | - | | - | | 649 | | 512 | | (0.8 | ) | 1.32 | |
| Tax matters (e) | - | | - | | - | | - | | 308 | | (44.0 | ) | 0.82 | |
| ADJUSTED | $ | 4,661 | | $ | 2,507 | | $ | - | | $ | 1,693 | | $ | 1,258 | | 22.1 | % | $ | 3.29 | |
| (a) | In 2015 we completed acquisitions including CHG Hospital Beds Inc. In 2014 we completed acquisitions including Patient Safety Technologies, Inc., Pivot Medical, Inc., Berchtold Holding, AG., and Small Bone Innovations, Inc. As a result, we incurred certain acquisition and integration related charges. |
| (b) | In both 2015 and 2014 we incurred certain restructuring related charges associated with focused workforce reductions, other restructuring activities and long-lived asset impairments. |
| (c) | Charges represent changes in our best estimate of the minimum end of the range of probable loss to resolve the recall of Rejuvenate and ABG II modular-neck hip stems and other recall matters. |
| (d) | Amount represents a gain associated with a legal settlement in 2015. |
| (e) | In 2015 and 2014 charges represent the tax impacts related to discrete tax items and the establishment of the European regional headquarters. |
HUG#1961000